Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: A post-hoc analysis in the FLAME study 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

Jadwiga A. Wedzicha,Dave Singh,Ioanna Tsiligianni,Christine Jenkins,Sebastian Fucile,Robert Fogel,Steven Shen,Pankaj Goyal,Karen Mezzi,Konstantinos Kostikas

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: A post-hoc analysis in the FLAME study 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

2019

Jadwiga A. Wedzicha
Dave Singh
Ioanna Tsiligianni
Christine Jenkins
Sebastian Fucile
Robert Fogel
Steven Shen
Pankaj Goyal
Karen Mezzi
Konstantinos Kostikas

Background The burden of chronic obstructive lung disease (COPD) is increasing in women, with recent evidence suggesting gender differences in disease characteristics and potentially in treatment outcomes.

Keywords:

Immunology
Indacaterol
Cardiorespiratory fitness
Post-hoc analysis
Obstructive lung disease
Disease
Biomedical sciences
COPD
Medicine
Diabetes mellitus
Internal medicine
copd patients
Salmeterol fluticasone
treatment response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations